space, a capillary with arterial (A) and venous (V) ends and a fat cell exposed to maximally effective insulin levels. All insulin-sensitive glucose transporters (GLUT4) are at the cell surface and glucose uptake (GU), arteriovenous (A-V) glucose difference, as well as arterio-ISF glucose difference are maximally stimulated. Red circles and red arrows indicate glucose molecules and glucose fluxes, respectively. B: Diagram illustrating the postulated saturation-type relationship between insulin concentration and insulin action. Dashed line indicates the maximally effective insulin concentration, beyond which insulin action is saturated and stable. Figure 2 Average time course of the intravenous glucose infusion rate (n=5, means±SE).
Online Appendix

Determination of the insulin reverse recovery:
The applied dual-pump mode of catheter operation (Fig. 1 ) allowed the insulin solution entering the catheter to be split into two main flow fractions. One was guided across the perforations and membrane pores of the MP and MD catheter, respectively, to the surrounding tissue (tissuedirected flows; Fig. 1 , thin straight arrows). The magnitude of this flow fraction and, hence, the amount of insulin transported to the tissue via convection was controlled, by controlling the difference between the speed of the inflow and outflow pump. The second flow fraction was guided along the entire catheter exchange region (i.e., along the perforated region of MP catheter or membrane region of MD catheter) to the outlet of the catheter (i.e., outlet-directed flow; Fig. 1 , bold striped arrows). When this fluid fraction passed by the exchange region of the catheter, diffusive bi-directional transport of solutes across the exchange channels (i.e., perforations of the MP catheter and membrane pores of the MD catheter; Fig. 1, wavy arrows) occurred. Thus, in addition to the convective insulin transport via the tissue-directed flows, insulin molecules contained in the outlet-directed flow partly diffused into the tissue when this fluid fraction passed by the exchange region of the catheter. To determine the extent of the diffusive insulin transport (i.e., insulin reverse recovery) in the MD and MP catheters, we measured the insulin concentration in the perfusate and in the catheter effluent samples obtained during the insulin delivery period of the study. To measure the insulin concentrations, a two-site enzyme immunoassay (Mercodia Ultrasensitive Insulin ELISA, Mercodia AB, Uppsala, Sweden) with a within-assay CV averaging 5 % was applied. The insulin reverse recovery (RR I ) for the catheters was calculated as RR I = (I in -I out ) / I in , where I in and I out are the measured insulin concentration in the perfusate and effluent sample, respectively. At outflow rates of ~0.47 µl/min, the efficiency of the diffusive transport of insulin across the exchange channels into the tissue (reverse recovery) was estimated to be 8 ± 2 and 5 ± 1 % for MP (n=5) and MD (n=5) catheters, respectively. The higher reverse recovery for insulin molecules in MP catheters compared to MD catheters was likely to be related to the difference in the size of the exchange channels (Ref. 1) of the applied catheters (MP perforations each with a diameter of 300 µm vs. MD membrane with pore size of ~1 µm and a molecular weight cut-off value of 20 kDa). Similar insulin reverse recoveries in MD catheters with comparable membrane surface and pore sizes were found in previous studies (e.g., Ref. 
